Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Reexamination Certificate
2006-05-02
2006-05-02
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
C424S475000, C424S489000, C424S465000, C514S951000
Reexamination Certificate
active
07037525
ABSTRACT:
The invention relates to formulations, e.g. film-coated tablets containing oxcarbazepine and to processes for the production of said formulations. The film-coated tablets have a tablet core comprising a therapeutically effective dose of oxacarbazepine being in a finely ground form having a mean particle size of from 4 to 12 μm (median value), and a hydrophilic permeable outer coating.
REFERENCES:
patent: 3716640 (1973-02-01), Schindler
patent: 4409212 (1983-10-01), Mondadori
patent: 4452738 (1984-06-01), Aufderhaar
patent: 4609675 (1986-09-01), Franz
patent: 4857336 (1989-08-01), Khanna et al.
patent: 4897270 (1990-01-01), Deutsch et al.
patent: 4945149 (1990-07-01), Matsumoto et al.
patent: 5231089 (1993-07-01), Bodor
patent: 5472714 (1995-12-01), Bourquin
patent: 5476654 (1995-12-01), Conte et al.
patent: 5840335 (1998-11-01), Wenzel et al.
patent: 5980942 (1999-11-01), Katzhendler et al.
patent: 6296873 (2001-10-01), Katzhendler et al.
patent: 0 435 826 (1990-12-01), None
patent: 0 646 374 (1995-04-01), None
patent: 835956 (1960-05-01), None
patent: 907309 (1962-10-01), None
patent: 1310120 (1970-03-01), None
patent: 2 195 248 (1988-04-01), None
patent: 904685 (1996-12-01), None
patent: 8-505379 (1994-01-01), None
patent: WO 94/13298 (1994-06-01), None
patent: WO 94/20110 (1994-09-01), None
patent: 95/29665 (1995-11-01), None
patent: 01/32183 (2001-05-01), None
* “Oxcarbazephine approved for partial seizures,” American Journal of Health-System Pharmacy, vol. 57(5), pp. 414-417, 1 (2000).
* Appel L. E. et al., “Formulation and Optimization of a Modified Microporous Cellulose Acetate Latex Coating for Osmotic Pumps,” Pharmaceutical Research, vol. 9, No. 12, pp. 1664-1667 (1992).
* Bodmeier R. et al., “Constant Potassium Chloride Release from Microporous Membraone-Coated Tablets Prepared with Aquous Colloidal Polymer Dispersions,” Pharmaceutical Research, vol. 8, No. 3 (1991).
* CA129:180164, Schlutermann, WO9835681, abstract.
* Degen, P.H. et al., “The Influence of Food on the Disposition of the Antiepileptic Oxcarbazepine and its Major Metabolities in Healthy Volunteers,” Biopharmaceutics & Drug Disposition, vol. 15(6), pp. 519-526, (1994).
* Fassihi A.R. et al., “Dissolution of Theophylline from Film-coated Slow Release Mini-tablets in Various Dissolution Media,” J. Pharm. Pharmacol., vol. 41, pp. 369-372 (1989).
* Heli Jung et al., “Influence of food on bioavailability of carbazepine,” Pharmaceutical Research, vol. 11(10) Supl,, p. s219 (1994).
* Lindholm T. et al., “Polysorbate 20 as a drug release regulator in ethyl cellulose film coatings,” J. Pharm. Pharmacol. vol. 38, pp. 686-688 (1986).
* McLean M.J., “Oxcarbazepine: Mechanisms of Action,” Epilepsia, vol. 35, S5-S9 (1994).
* Parikh N.H. et al., “Aqueous Ethylcellulose Dispersion of Ethylcellulose. I. Evaluation of Coating Process Variables,” Pharmaceutical Research, vol. 10, No. 4, pp. 525-534 (1993).
* Porter S.C. et al., “The permeability of enteric coatings and the dissolution rates of coated tablets,” J. Pharm. Pharmacol., vol. 34, pp. 5-8 (1982).
* Schwabe S., “Clinical Development Outlook of Oxcarbazepine,” Epilepsia, vol. 35, S2-S4 (1994).
Nurnberg E. et al., Methoden, Springer-Verlag, 1990, Chapt. 3, “Verarbeitung von Stoffen,” pp. 534-549.
O'Connor R.E., et al., “Powders,” Chapter 88, pp. 1615-1632 (1985).
M. Gibaldi, Biopharmaceuticals and Clinical Pharmacokinetics, 4thEdition, Lea & Febiger, Philadelphia, p. 51, (1991).
G.S. Banker, C.T. Rhodes, Marcel Dekker, Modern Pharmaceuticals, pp. 133, 335, 336, 3rdEdition, New York, (1995).
Remington, “The Science and Practice of Pharmacy”, 19thEdition, pp. 1449, (1995).
Extract from M-Tec website, no date.
SPC for Trileptal Available from the eMC, no date.
N. Kitamori, “Effect of Drug Content and Drug Particle Size on the Change in Particle Size During Tablet Compression”, J. Pharm. Pharmacol. vol. 31, pp. 505-507, (1979).
S.H. Yalkowasky, S. Bolton, “Particle size and Content Uniformity”, Pharmaceutical Research vol. 7, pp. 962-966, no date.
M. Dam et al. Euro. J. of Clin. Pharmacol, vol. 2, pp. 59-64, (1981).
M. Dam and P. Jensen, Antiepileptic Drugs, 3rdEdition, Chapter 66, pp. 913-924, (1989).
Raj Suryanarayanan, Powder Diffraction, vol. 5, No. 3, pp. 155-159, (1990).
Noyes and Whitney, JACS, vol. 19, pp. 930-932, (1897).
Translation of the relevant parts of Rudolf Voigt, Lehrbuch der pharmazeutischen Technoloige, 6thEdition, pp. 635-638.
Trileptal Basic Drug Information Issued Mar. 24, 1993.
Report B 84/ 1989 “GP 47 680, Oxcarbazepine” dated Oct. 3, 1989.
Clinical Pharmacology Report No. 47680 02 029 dated Jul. 17, 1998.
Degan et al, “The Influence of Food on the Disposition of the Antiepileptic Oxcabazepine and its Major Metabolites in Healthy Volunteer”, Biopharmaceuticals & Drug Disposition, vol. 15, pp. 519-526. (1994).
Heidi Jung, “Influence of Food on Bioavailability of Oxcarbazepine”, Abstract.
Hawes Pili A.
Novartis AG
Page Thurman K.
Waibel Peter J.
Wilusz, Jr. E Jay
LandOfFree
Oxacarbazepine film-coated tablets does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oxacarbazepine film-coated tablets, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxacarbazepine film-coated tablets will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3557733